Three different types of PET imaging are currently used in the assessment of AD: glucose metabolism using [18F]-2-fluoro-2-deoxy-D-glucose (FDG) PET (FDG-PET), and amyloid or tau deposition using amyloid-β PET (Aβ-PET) or Tau-PET [33,34,35]. Here, MAPT is linked to Alzheimer disease.